The administration of the synthetic peptide YMESRADR with a low aspirin dose significantly augments its antiplatelet effect, in contrast to the highly constrained peptide (S,S) PSRCDCR-NH2. An experimental study.
Hellenic J Cardiol
; 65: 56-58, 2022.
Article
in En
| MEDLINE
| ID: mdl-35104677
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Platelet Aggregation Inhibitors
/
Aspirin
Limits:
Humans
Language:
En
Journal:
Hellenic J Cardiol
Journal subject:
CARDIOLOGIA
Year:
2022
Document type:
Article
Country of publication:
Países Bajos